Impact of Azithromycin on Forsythiaside Pharmacokinetics in Rats: A Population Modeling Method

Abstract

Objective

Lianhuaqingwen and Shuanghuanglian are drug treatment options for Corona Virus Disease 2019 (COVID-19). In China, use of traditional Chinese medicine with Shuanghuanglian or Lianhuaqingwen (for them, forsythiaside is the active antiviral and antibacterial component) in combination with azithromycin is common for the treatment of pediatric pneumonia. It is important to understand the reason why the combination of these compounds is better than a single drug treatment. This study aimed to explore the pharmacokinetic interaction between forsythiaside and azithromycin.

Methods

Twelve male Sprague-Dawley rats were randomly divided into an experimental group (Forsythia suspensa extract and azithromycin) and a control group (a single dose of Forsythia suspensa extract in 5% glucose solution). Plasma samples were collected at scheduled time points, and the high-performance liquid chromatography combined with ultraviolet method was used to determine the plasma forsythiaside concentration. Non-compartmental analysis and population pharmacokinetic methods were used to investigate the forsythiaside pharmacokinetic difference between the experimental and control group.

Results

Compared with a single administration, the area under the curve and half-life of forsythiaside increased, and forsythiaside clearance decreased significantly after co-administration with azithromycin. The in vivo behavior of forsythiaside could be described by the one compartment model. The forsythiaside clearance decreased when combined with azithromycin. Visual evaluation and bootstrap results suggested that the final model was precise and stable.

Conclusion

Co-administration of azithromycin can significantly decrease the forsythiaside clearance and increase drug exposure. A lower dose of azithromycin can obtain sufficient forsythiaside concentration to provide antiviral and antibacterial activity.

References

[1] RunfengL, YunlongH, JichengH, et al.. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res, 2020, 156: 104761

[2] WangL, XuX, RuanJ, et al.. Quadruple therapy for asymptomatic COVID-19 infection patients. Expert Rev Anti Infect Ther, 2020, 18(7): 617-624

[3] LuH. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends, 2020, 14(1): 69-71

[4] NiL, ZhouL, ZhouM, et al.. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front Med, 2020, 14(2): 210-214

[5] WangF, CaoGS, LiY, et al.. Characterization of forsythoside A metabolites in rats by a combination of UHPLC-LTQ-Orbitrap mass spectrometer with multiple data processing techniques. Biomed Chromatogr, 2018, 32(5): e4164

[6] ZhangS, ShaoSY, SongXY, et al.. Protective effects of Forsythia suspense extract with antioxidant and anti-inflammatory properties in a model of rotenone induced neurotoxicity. Neurotoxicology, 2016, 52: 72-83

[7] WuZQ, LiuGH, YanLJ, et al.. Experimental study on anti-influenza virus infection with yinqiao-decoction by orthogonal design. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (Chinese), 2010, 24(6): 427-429

[8] ZengXY, YuanW, ZhouL, et al.. Forsythoside A exerts an anti-endotoxin effect by blocking the LPS/TLR4 signaling pathway and inhibiting Tregs in vitro. Int J Mol Med, 2017, 40(1): 243-250

[9] LawAH, YangCL, LauAS, et al.. Antiviral effect of forsythoside A from Forsythia suspensa (Thunb.) Vahl fruit against influenza A virus through reduction of viral M1 protein. J Ethnopharmacol, 2017, 209: 236-247

[10] QuH, ZhangY, WangY, et al.. Antioxidant and antibacterial activity of two compounds (forsythiaside and forsythin) isolated from Forsythia suspensa. J Pharm Pharmacol, 2008, 60(2): 261-266

[11] BakheitAH, Al-HadiyaBM, Abd-ElgalilAA. Azithromycin. Profiles Drug Subst Excip Relat Methodol, 2014, 39: 1-40

[12] MaWG, JiaJM. The effects and prospects of the integration of traditional Chinese medicine and Western medicine on andrology in China. Asian J Androl, 2011, 13(4): 592-595

[13] LampeH, HalleB, FreundM. Western and Chinese medicine in oncology and hematology. Forsch Komplementmed, 2011, 18(4): 185-191

[14] ZhangC, WangY, ZhaoX, et al.. Prediction of Recurrent Stroke or Transient Ischemic Attack After Noncardiogenic Posterior Circulation Ischemic Stroke. Stroke, 2017, 48(7): 1835-1841

[15] QingGC, ZhangH, BaiY, et al.. Traditional Chinese and Western Medicines Jointly Beat COVID-19 Pandemic. Chin J Integr Med, 2020, 26(6): 403-404

[16] RenJL, ZhangAH, WangXJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res, 2020, 155: 104743

[17] YangY, IslamMS, WangJ, et al.. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. Int J Biol Sci, 2020, 16(10): 1708-1717

[18] LiuN, ChenX, YinL. Clinical effect of azithromycin sequential therapy combined with shuanghuanglian oral solution on pediatric mycoplasma pneumonia and the impact on serum inflammatory cytokines levels and immunologic function. Pract J Cardiac Cereb Pneum Vasc Dis, 2016, 24(9): 94-97

[19] WangH. Efficacy of shuanghuanglian oral liquid only for children combined with azithromycin in the treatment of mycoplasma pneumonia in children. Chin Foreign Med Res, 2018, 16(7): 25-27

[20] TianJ, SunS, ZhaoZ, et al.. Pharmacokinetic interaction between shuanghuanglian and azithromycin injection: a nonlinear mixed-effects model analysis in rats. Xenobiotica, 2019, 49(11): 1344-1351

[21] TianJC, LinLF, LiXC, et al.. Forsythiaside stability in pretreated rat plasma and its pharmacokinetics after i.v. administration. Anal Methods-Uk, 2015, 7(5): 1809-1815

[22] WangH, LiX, SunS, et al.. Population Pharmacokinetics and Dosing Simulations of Ceftazidime in Chinese Neonates. J Pharm Sci, 2018, 107(5): 1416-1422

[23] HookerAC, StaatzCE, KarlssonMO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res, 2007, 24(12): 2187-2197

[24] ZhangL, YuJ, ZhouY, et al.. Becoming a Faithful Defender: Traditional Chinese Medicine against Coronavirus Disease 2019 (COVID-19). Am J Chin Med, 2020, 48(4): 763-777

[25] LiT, LuH, ZhangW. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect, 2020, 9(1): 687-690

[26] HoLTF, ChanKKH, ChungVCH, et al.. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19. Eur J Integr Med, 2020, 36: 101116

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology